Home » Topics » BioWorld Science

BioWorld Science
RSS

Pfizer to evaluate Atomwise's platform for drug discovery

Sep. 18, 2018

GlaxoSmithKline patents hepatitis B e-antigen and/or surface antigen secretion inhibitors

Sep. 18, 2018

CRISPR Therapeutics and ViaCyte partner on gene-edited allogeneic stem cell therapies for diabetes

Sep. 18, 2018

Galapagos, AbbVie Sarl present mutant CFTR modulators

Sep. 18, 2018

Phenex Pharmaceuticals identifies aryl hydrocarbon receptor antagonists

Sep. 18, 2018

Toll-like receptor 4 antagonists discovered at TaiwanJ Pharmaceuticals

Sep. 18, 2018

Biogen presents phase II data for BG-00011 in IPF patients

Sep. 18, 2018

FDA lifts partial clinical hold for XMT-1522

Sep. 18, 2018

Patient recruitment starts in two phase II trials of DMX-200 in kidney disease

Sep. 18, 2018

ALZ-801-derived 3-sulfopropanoic acid prevents Abeta42 oligomerization in Alzheimer's disease

Sep. 18, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...